Since those regulatory approvals, T-DXd has been approved to treat other solid tumors, specifically HER2-mutant metastatic non-small cell lung cancer and HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma [6]. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.